What is the controversy over the spinal muscular atrophy drug in Keralam?

A Keralam government initiative to widen access to treatment for spinal muscular atrophy (SMA) has run into controversy after the programme switched from a branded drug to a generic one. Parents of children with SMA, a rare genetic disorder that progressively weakens muscles and affects breathing, want the branded version back. A label on a drug bottle has raised concerns, and political parties have joined the row.